 SALT LAKE CITY, Sept. 29, 2021 PRNewswire -- Recursion NASDAQ: RXRX, a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that the U.S. Food and Drug Administration FDA has granted the company orphan drug designation for REC-4881 for the potential treatment of familial adenomatous polyposis FAP. 